Marken James G.'s Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Mar 7, 2024
- Accession no.
- 0001579587-24-000006
- Filed
- Mar 7, 2024
- Trade date
- Mar 7, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.62M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Marken James G.CIK 0001579587 | Officer (SVP OPS & PROD DEV) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | Common Stock | SSaleDisposed | −24,338 | $66.37F1 | −$1,615,313.06 | 124,492 | Direct | |
| Mar 7, 2024 | Common Stock | FTax withholdingDisposed | −2,034 | $66.71 | −$135,688.14 | 122,458 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were sold in multiple trades at prices ranging from $66.00 to $66.75. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.